Back to IQV
IQV Stock: Growth, Valuation and Risks
$IQVBULLISHHealthcare

IQV Stock: Growth, Valuation and Risks

IQVIA reported stronger-than-expected third-quarter earnings and rising clinical bookings, while analysts remain broadly positive. The shares have advanced sharply in recent months, leaving valuation, debt and execution risks important to weigh alongside growth prospects.

November 14, 202611 min read
Current Price
$265.12
-2.21%
Analyst Rating
Strong Buy
Price Target
$291.33
9.9% upside
P/E Ratio
31.87

Executive Summary

Investment Thesis: IQVIA combines clinical research services with healthcare data, technology and commercial solutions, giving it several ways to benefit from pharmaceutical research demand and wider adoption of analytics and AI. Its latest reported quarter beat the supplied EPS estimate, while management commentary summarized in recent coverage points to increased bookings and raised guidance. The share-price advance and elevated leverage complicate the picture, so the business outlook and the price investors pay deserve equal attention.

Current Price: $265.12 as of Friday, November 13 | Key Metric: Third-quarter 2026 EPS of $3.34 versus $3.26 estimated | Stance: BULLISH, reflecting the available operating and analyst signals, not an investment recommendation

Company Overview

IQVIA Holdings Inc. provides services and technology to pharmaceutical, biotechnology and other healthcare companies. Its work spans clinical trial design and execution, healthcare data and analytics, and commercial services that help clients bring products to market.

The combination matters because drug developers need both research capabilities and information about patients, providers and markets. IQVIA’s scale and specialized datasets can support repeat business, although customer budgets, trial activity and competition can still affect growth.

Key Products & Competitive Position

  • Core Business: Clinical research services, data and technology solutions, and commercial services for the life sciences industry.
  • Key Products: Clinical trial management and related research services, healthcare data and analytics, technology platforms, and sales and marketing support.
  • Competitive Moat: A broad global operating network, accumulated healthcare data, established client relationships and the ability to combine research, analytics and commercial services. These advantages can support retention, but they do not eliminate competition or execution risk.

Recent Developments

Recent company coverage highlights $3.2 billion in net new clinical bookings in the third quarter and a 14% increase in last-12-month net new bookings to $11.7 billion. News summaries also point to AI adoption and operating efficiencies as contributors to the growth narrative. These are constructive indicators, but bookings are not the same as recognized revenue: delivery timing, cancellations and conversion into completed work remain important to monitor.

Financial Snapshot

Market Cap$43.69B
P/E Ratio31.87
52-Week Range$154.50 - $284.50
Dividend Yield0.0% reported
EPS (TTM)$8.46
ROE21.82%

Revenue & Earnings Trends

Available financial data shows trailing revenue of approximately $17.31 billion, revenue growth of 8.0% and earnings growth of 8.8%. Gross margin is reported at 33.07%. The latest supplied quarterly result is encouraging: Q3 2026 non-GAAP EPS was $3.34, above the $3.26 estimate, a beat of about 2.5%.

There is a small data discrepancy worth noting. The supplied company metrics list trailing EPS at $8.46, while the Yahoo Finance extract lists trailing EPS at $8.22 and return on equity at 21.39%, rather than 21.82%. Different dates or calculation methods may account for the differences. The figures in the snapshot use the primary metrics provided for this report.

Balance Sheet Highlights

IQVIA had about $2.42 billion of cash against approximately $16.31 billion of debt in the supplied financial extract. Debt-to-equity is listed at 240.23%, while the current ratio is 0.83 and quick ratio is 0.74. Free cash flow of roughly $2.12 billion and operating cash flow of $2.74 billion provide meaningful cash generation, but debt servicing and refinancing remain relevant considerations.

Valuation Analysis

Current Valuation Metrics

Forward P/E18.7Calculated from $265.12 and $14.20 forward EPS
PEG Ratio1.00Provider-reported, growth-adjusted
EV/EBITDA18.51Provider-reported, historical comparison unavailable
P/S Ratio2.52Calculated from market cap and trailing revenue

Historical Comparison

A comparable five-year average valuation was not supplied, so a precise historical premium or discount cannot be established here. The available provider data places enterprise value at 3.33 times revenue and 18.51 times EBITDA. Those metrics indicate that investors are assigning a meaningful value to IQVIA’s scale and cash generation, but they should be assessed against growth durability, capital requirements and peers rather than viewed in isolation.

Fair Value Estimate

Analyst target data supplied for this report gives a mean of $291.33, about 9.9% above the Friday close, with a range of $240 to $346. A separate Yahoo Finance extract shows a higher mean target of $311.89 and a different low target, illustrating that targets vary by provider and update date. These are forecasts, not intrinsic-value measurements. A discounted cash-flow estimate would require explicit assumptions about future growth, margins, taxes, investment and discount rates, which are not available in the provided data.

Competitive Landscape

Market Position

Market Share: Not established by the available data | Ranking: A major global provider across clinical research and life-sciences data services

Key Competitors

$ICLRICON, a contract research organization providing clinical development services to drug developers.
$MEDPMedpace, a clinical research organization focused on drug and medical-device development.
$CRLCharles River Laboratories, a research services provider supporting drug discovery and development.

Competitive Advantages

  • Integrated services: IQVIA can serve clients across research, data and commercial activities, which may simplify vendor relationships and support cross-selling.
  • Data and analytics: Proprietary healthcare information and analytical capabilities can help clients design studies and make commercial decisions. Data quality, privacy compliance and client value remain essential.
  • Scale and relationships: Global delivery capabilities and established customer ties may help IQVIA compete for complex projects, although smaller specialists and other large providers remain credible alternatives.

Earnings Track Record

Last 4 Quarters: 1 documented beat / 0 documented misses, with three quarter-by-quarter results not provided

Recent Earnings History

Q3 2026$3.34 vs $3.26 estimateBEAT
Q2 2026Quarterly comparison not suppliedUNAVAILABLE
Q1 2026Quarterly comparison not suppliedUNAVAILABLE
Q4 2025Quarterly comparison not suppliedUNAVAILABLE

Guidance Trend

Recent coverage reports that IQVIA raised guidance after its third-quarter results, but the revised numerical ranges were not included in the supplied material. The positive signal is that management apparently increased expectations following the quarter. For a fuller assessment, compare the next reported revenue and adjusted EPS with the updated company outlook, and check whether bookings convert into delivered work and cash flow.

Analyst Sentiment

Consensus Rating: Strong Buy, based on the supplied analyst survey

Strong Buy: 2 Buy: 16 Hold: 2 Sell: 0, Strong Sell: 0

Price Targets

  • Low: $240
  • Mean: $291.33 (approximately 9.9% above the Friday close)
  • High: $346

Recent Analyst Actions

Provider-reported actions after the earnings release include target increases from TD Cowen to $307, JPMorgan to $325, Truist Securities to $346 and Evercore ISI to $310, with their ratings maintained. The supplied analyst survey counts 20 opinions, while the separate provider extract lists 18 and a different average target. These differences reinforce that consensus is a snapshot, not a single definitive valuation.

Recent News & Catalysts

Key Developments

  • Q3 earnings beat: IQVIA reported EPS of $3.34 versus the supplied $3.26 estimate on October 27, 2026. Recent news summaries also describe the quarter as exceeding revenue estimates.
  • Clinical bookings: Third-quarter net new clinical bookings were reported at $3.2 billion, and trailing twelve-month net new bookings reached $11.7 billion, up 14%. Converting these bookings into revenue is a key follow-through measure.
  • Recent share performance and ownership changes: A November 13 Zacks article cited a 58.8% six-month share-price gain and discussed research demand, commercial momentum, AI and efficiency. A separate filing-based report said CenterBook Partners reduced its position substantially. Neither a short-term return nor one manager’s portfolio change determines the company’s fundamental outlook.

Upcoming Catalysts

Next Earnings: Expected February 4, 2027, with supplied EPS estimate of $3.60 | Key Events: Conversion of bookings, updated guidance, clinical research demand and evidence that AI and efficiency initiatives support margins

Technical Outlook

Current Price: $265.12 as of Friday, November 13 vs 52-Week High: $284.50 (about 6.8% below the high)

Trend Analysis

IQV closed Friday down $5.99, or 2.21%, from the prior close of $271.11. The Friday range was $263.50 to $272.12. The shares remain well above the 52-week low of $154.50, following a strong advance described in recent coverage. Markets are closed Saturday, November 14; the next US trading session is Monday, November 16. A one-day decline does not by itself establish a change in trend, and no moving-average or volume series was supplied to confirm technical momentum.

Key Levels

  • Resistance: $272.12, the reported Friday high, then the 52-week high at $284.50.
  • Support: $263.50, the reported Friday low, then the $240 analyst low target as a reference point only, not a technically confirmed support level.

Bull vs Bear Case

Bull Case

  • Catalyst 1: The Q3 EPS beat and reported revenue outperformance indicate that recent operating performance exceeded expectations.
  • Catalyst 2: Higher net new bookings and demand for clinical research could support future revenue, while analytics and AI initiatives may improve client offerings and operating efficiency.
  • Catalyst 3: The supplied analyst mean target of $291.33 is above the Friday close, and several firms raised targets after earnings. Targets remain opinions, not guaranteed outcomes.

Bull Scenario Reference: $346, the supplied high analyst target, approximately 30.5% above the Friday close

Bear Case

  • Risk 1: The shares have advanced sharply over a relatively short period, which can leave the price vulnerable if growth expectations or guidance disappoint.
  • Risk 2: Debt of about $16.31 billion, a 240.23% debt-to-equity reading and current ratio below 1 make balance-sheet flexibility important to track.
  • Risk 3: Competition, delayed trial starts, customer budget pressure or slower booking conversion could weigh on growth and challenge the valuation.

Bear Scenario Reference: $240, the supplied low analyst target, approximately 9.5% below the Friday close

Risks to Consider

  • Valuation Risk: A P/E of 31.87 and EV/EBITDA of 18.51 leave the shares sensitive to changes in growth, margins and investor expectations. The forward P/E calculation uses provider forward EPS and may not be directly comparable with the trailing P/E methodology.
  • Competitive Risk: Other contract research organizations and healthcare-data providers compete for client work. Pricing pressure or loss of important contracts could affect utilization and margins.
  • Macro Risk: Biopharmaceutical funding, interest rates, public-health policy and customers’ research budgets can influence trial starts and project timing. A weaker funding environment may slow the conversion of bookings to revenue.
  • Execution Risk: IQVIA must deliver complex studies across geographies while protecting sensitive data and meeting regulatory requirements. Integration of technology and AI into client workflows also requires reliable execution and demonstrable returns.

Bottom Line

Investment Verdict: BULLISH market-analysis stance

IQVIA’s latest earnings beat, booking growth and broad analyst optimism support a positive operating narrative. That narrative is tempered by a recent share-price run-up, significant debt, near-term liquidity measures below 1 and conflicting provider target data. The balance of evidence is constructive, but outcomes depend on revenue conversion, cash generation and execution against guidance.

Action Items for Investors

  • Long-term investors: Track reported revenue, bookings conversion, free cash flow and debt reduction over several quarters; these measures help test whether the growth narrative is translating into durable financial results.
  • Short-term traders: Treat Friday’s range and the 52-week high as reference points, not forecasts. The next US session is Monday, November 16, and near-term price action can remain volatile after a sizable advance.
  • Risk management: Consider how concentration, valuation sensitivity and leverage fit within your own risk limits. This report is informational and does not provide personalized investment advice.

What to Watch This Week

  • Whether IQV holds near Friday’s $263.50 intraday low or moves back toward the $272.12 high, while recognizing these are short-term reference levels.
  • Any new company commentary or industry data on clinical trial demand, booking conversion and pharmaceutical research budgets.
  • Updates to analyst estimates and targets, keeping in mind that the supplied consensus figures differ by source and date.

Data note: US markets were closed on Saturday, November 14, 2026. Price and daily-change references in this report are for Friday, November 13. Financial and analyst figures are drawn from the supplied data and may differ across vendors, dates and accounting definitions.

Share this report

Share this article

Spread the word on social media

Think IQV will outperform? Prove it.

Free practice contests — earn Alpha Coins
Enter a Contest

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.

Spotted something wrong? Report an error.